Boswellia for Arthritis: The Best Supplement You Haven't Tried?
Frankincense extract improved every OA measure across 7 trials, sometimes within a week. Why boswellia looks promising, and the caveats that keep it honest.
Boswellia serrata (frankincense, the actual biblical resin) has quietly assembled one of the tidier evidence files in the arthritis supplement aisle: a meta-analysis of seven randomized trials found it improved pain, stiffness, and function, every osteoarthritis measure tested, per BMC Complementary Medicine and Therapies. It's less famous than turmeric and less marketed than CBD, which makes it exactly the kind of candidate this site likes to examine properly: promising numbers, small trials, and caveats that deserve equal billing. Both halves follow.
The case for
Boswellic acids (AKBA is the star) inhibit an inflammatory enzyme pathway that conventional NSAIDs largely leave alone, giving boswellia a plausible mechanism rather than just folklore. And the trial numbers are consistent: across the pooled studies (545 patients), boswellia beat placebo on visual-analog pain, WOMAC pain, stiffness, and function, with the meta-analysis recommending at least four weeks of use to judge it.
The landmark trial is worth knowing specifically: 75 knee OA patients took an AKBA-enriched extract (100 or 250 mg/day) or placebo for 90 days. Both doses delivered clinically and statistically significant improvements in pain and function, and the higher dose started showing benefits within seven days, remarkable speed for a supplement, alongside reduced levels of a cartilage-degrading enzyme in joint fluid, published in Arthritis Research & Therapy. The Arthritis Foundation's guide cites a Cochrane review finding boswellia reduced OA pain by nearly 20 points without serious side effects.
Safety looks clean in the trial record: NCCIH notes doses up to 1,000 mg daily used safely for up to six months, and calls boswellia "likely to be safe when taken orally."
The case for keeping your enthusiasm on a leash
Honest counterweights, because this site always carries them:
- The trials are small. Seven trials, 545 total patients; the landmark study was 75 people. NCCIH's bottom line is blunt: "there is not enough high-quality evidence to determine whether boswellia is useful for any health condition," with the OA signal described as promising but needing larger, better studies.
- Industry fingerprints. The flagship 5-Loxin trial was run by researchers affiliated with the extract's manufacturer. That doesn't make it wrong; it makes independent replication the thing to wish for.
- The bottle problem. Extracts vary widely in boswellic-acid standardization, so "boswellia 300 mg" on two different labels can mean very different actual doses. Trials used standardized, AKBA-enriched extracts; a bargain unstandardized powder is testing a different product.
- Interactions exist: the Arthritis Foundation flags potential interactions including antidepressants and immunosuppressants, and urges care in autoimmune conditions, which describes a lot of this site's readers. Check with a pharmacist, particularly if you're on RA or psoriatic-arthritis therapy.
Net grade: among OA supplements, boswellia sits near the top of the "promising" tier with turmeric, ahead of ginger's modest showing and far ahead of the debunked aisle, while still short of "proven."
Testing it properly
- Buy standardized. Look for a stated boswellic-acid or AKBA percentage; trial doses ran 100-250 mg/day of enriched extract, and NCCIH cites up to 1,000 mg/day of general extract as safely used.
- Run a four-to-twelve-week trial. The meta-analysis floor is four weeks; the landmark trial ran ninety days. The seven-day early signal is a nice bonus if you get it, not a failure if you don't.
- Baseline first, judge from the log. A week of recorded pain scores before the first capsule, then the comparison at week four and twelve. Flare keeps the log and pairs it with the weather, which matters here more than most: a supplement started in a stormy week and judged in a calm one gets free credit it didn't earn.
- One variable at a time. Boswellia stacked on new turmeric, new shoes, and a new exercise plan produces a good month and no knowledge. Sequence your experiments.
FAQ
Does boswellia work for arthritis?
The pooled trial evidence for osteoarthritis is genuinely positive across pain, stiffness, and function, but trials are small and NCCIH considers the evidence not yet high-quality. Grade: promising, unproven.
What boswellia dose do studies use?
100-250 mg/day of AKBA-enriched standardized extract in the landmark trial; NCCIH cites up to 1,000 mg/day of extract used safely for up to six months.
How fast does boswellia work?
The higher-dose group in the key trial improved within seven days, but the meta-analysis recommends at least four weeks before judging.
Is boswellia safe to take?
Trial safety looks clean and NCCIH calls it likely safe orally, with flagged interaction cautions (antidepressants, immunosuppressants, autoimmune conditions) worth a pharmacist check.
Sources
Yu et al., BMC Complementary Medicine and Therapies 2020 (meta-analysis) · Sengupta et al., Arthritis Research & Therapy 2008 (5-Loxin RCT) · NCCIH — Boswellia · Arthritis Foundation — Supplement and Herb Guide
This article is for informational purposes only and is not a substitute for professional medical advice. Check with your doctor or pharmacist before starting boswellia, especially with antidepressants, immunosuppressants, or autoimmune disease.
